RxDoctor Payments Data

Sofia Masri, MD

Advanced Heart Failure and Transplant Cardiology · Madison, WINPI 1053465658

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Abbott at 53.9% of the total.

$5,601in general payments, 2019–2025

Across 29 payments — averaging $193.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Livanova USA, Inc.$2K
  • Abiomed$202
  • Janssen Scientific Affairs, LLC$116
  • Novo Nordisk$111
  • Medtronic$97
  • plus $255 from 7 others
$125,982in research payments, 2019–2025

Across 12 payments — averaging $10,499 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$126K

What the payments were for

  • Consulting fees$1,50027%
  • Speaking & faculty fees$2,30041%
  • Travel & lodging$4779%
  • Food & beverage$1,27523%
  • Education$491%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Wisconsinto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$66,795
Medicare patients
307
Services billed
883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndaqelTafamidis Meglumine11$230,916
EntrestoSacubitril/Valsartan65$65,886
EliquisApixaban36$43,893
FarxigaDapagliflozin Propanediol36$32,260
JardianceEmpagliflozin36$21,954
Tacrolimus26$4,110
Metoprolol Succinate95$1,762
Bumetanide24$1,658
Rosuvastatin Calcium27$986
Atorvastatin Calcium46$887
Amiodarone Hcl14$506
Valsartan14$413
Warfarin Sodium24$351
Losartan Potassium30$300
Famotidine15$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndaqel, Eliquis$43$274,80947 claims
AstraZenecaFarxiga$14$32,26036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Wisconsinon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →